INTELLIGENT BIO SOLUTIONS INC. Q3 FY2022 earnings call

• Clinical advancements: In March, IRB approval to initiate subject enrollment for a study on saliva-based glucose testing with 40 adults with type 2 diabetes. Key collaborators like Quest Diagnostics and Johns Hopkins Hospital are evaluating samples. Dr. David Klonoff is the primary investigator. - Manufacturing achievements: Development plant construction in Australia is in final stages, with land identified on the University of Newcastle campus, anticipating groundbreaking in the back half of next quarter. Critical equipment sourcing completed, with initial delivery expected in June. - Financials: For Q3 2022, net loss was $1.34 million or $0.09 per share vs. $3.14 million or $0.27 per share in same period 2021. Government support income was $192,500, up from $34,290 in 2021. Cash, cash equivalents, and marketable securities totaled ~$10.7 million as of March 31, 2022, vs. $12.5 million on June 30, 2021.

No specific product segment financial performance details provided in the transcript.

• Based on current operating plan and financial resources, cash, cash equivalents, and marketable securities as of March 31, 2022, will be sufficient to cover expenses and capital requirements well into the first half of 2023 and remains unchanged from last quarter.

• Forward-looking statements involve risks and uncertainties such as ability to develop and commercialize diagnostic tests, realized commercial benefit from partnerships and collaborations, and secure regulatory approvals. These statements are predictions and involve known and unknown risks, uncertainties, etc. as per company's public filings.

Q: Regarding the LSBD stake, do you anticipate it to be stable going forward?

A: Dr. Steven Boyages stated LSBD's stake is now down to zero.

Q: On the manufacturing facility build, is it a greenfield build or using existing infrastructure?

A: Spiro Sakiris said it will be a new build with land identified on the University of Newcastle campus.

Q: When do you anticipate the first enrollee in the glucose collection study?

A: Dr. Steven Boyages said 10 out of 40 patients already completed, aiming for 15 this week, data collection to be complete by end of May, with analysis done by end of June.

Q: Do you need final data from the collection study before starting to develop the correlation algorithm?

A: Dr. Steven Boyages said final data will inform the specifics of the next phase of studies, and the next design phase won't take long